Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
ASCO Annual Meeting
Biomarker Identifies Patients with Rare Brain Tumors Who Have a Survival Benefit from Chemotherapy Plus Radiation
By
Phoebe Starr
ASCO Annual Meeting
,
ASCO
June 2012, Vol 3, No 4
Patients with the relatively rare brain tumor anaplastic oligodendroglioma who were treated with adjuvant chemotherapy after standard radiation therapy had improved survival compared with radiation alone, especially if they had codeletion of chromosomes 1p/19q, according to long-term follow-up of the EORTC (European Organisation for Research and Treatment of Cancer) 2651 study reported at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Read Article
Comparing the Value of Denosumab versus Zoledronic Acid in Preventing Cancer-Related Skeletal Events
By
Caroline Helwick
ASCO Annual Meeting
August 2011, Vol 2, No 5
Chicago, IL—Two agents are vying to be the preferred option for bone protection in patients with cancer—the blockbuster drug zoledronic acid (ZA; Zometa, Reclast) and the newer drug denosumab (Prolia), which was approved last year for the prevention of skeletal-related events (SREs) in patients with cancer.
Read Article
Prolonged Treatment with Imatinib for High-Risk GIST Increases Survival, Reduces Recurrence
By
Audrey Andrews
ASCO Annual Meeting
August 2011, Vol 2, No 5
Chicago, IL—Results from a phase 3 clinical trial presented at a plenary session at ASCO 2011 could lead to prolonged treatment with adjuvant imatinib for gastrointestinal stromal tumors (GIST).
Read Article
The Oncology Drug Pipeline Is Promising
By
Neil Canavan
ASCO Annual Meeting
August 2011, Vol 2, No 5
Studies presented at the 2011 annual meeting of the American Society of Clinical Oncology (ASCO) suggest that patients with metastatic mel anoma or with non– small-cell lung cancer (NSCLC)—2 disease states with very high rates of mortality—may soon have new treatment options.
Read Article
Off-Label Drug Use, Advanced Technologies Driving Up Medicare Cost of Cancer Care
By
Neil Canavan
ASCO Annual Meeting
August 2011, Vol 2, No 5
Chicago, IL—A series of studies presented at this year’s ASCO annual meeting suggest that the use of unwarranted high-cost imaging procedures, a surge in the use of innovative treatment technologies, and off-label use of supportive cancer agents are helping to escalate Medicare costs, leading researchers to suggest that further regulation may be needed to rein in unnecessary expenses.
Read Article
Impressive Results with New Drugs for Advanced Prostate Cancer
By
Neil Canavan
ASCO Annual Meeting
August 2011, Vol 2, No 5
Chicago, IL—The potential of 2 novel agents still in clinical trials, and 1 drug that was recently approved, offer new hope to patients with metastatic castrate-resistant prostate cancer (mCRPC), a disease with a dire prognosis and few good current treatment options.
Read Article
Bevacizumab Maintenance Reduces Disease Progression Risk in Ovarian Cancer
By
Audrey Andrews
ASCO Annual Meeting
August 2011, Vol 2, No 5
Chicago, IL—The “big news” in metastatic ovarian cancer presented at ASCO 2011 involved the investigational poly (ADP-ribose) polymerase (PARP) inhibitor olaparib, which prolonged progression-free survival (PFS) by nearly 4 months versus placebo.
Read Article
Emerging Regimen for Metastatic Pancreatic Cancer Has Survival Benefit, but Is It Cost-Effective?
By
Neil Canavan
ASCO Annual Meeting
August 2011, Vol 2, No 5
Chicago, IL—A cost analysis presented at ASCO 2011 and performed at the University of Toronto, Odette Cancer Center, Ontario, showed that the emerging combination regimen that includes oxaliplatin (Eloxatin), irino tecan (Camptosar), fluorouracil (Adrucil) and leucovorin (FOLFIRINOX) is not cost-effective when considered within the framework of a willingness-to-pay threshold of $100,000 per quality-adjusted life-year (QALY).
Read Article
New Regimen with an Old Drug Boosts Survival in Pediatric ALL
ASCO Annual Meeting
August 2011, Vol 2, No 5
Chicago, IL—The use of high-dose methotrexate (HD-MTX) has demonstrated a significant improvement in event-free survival in patients with pediatric acute lymphoblastic leukemia (ALL) at 5 years compared with the standard regimen.
Read Article
Genome-Forward Medicine in Lung Cancer
By
Caroline Helwick
ASCO Annual Meeting
August 2011, Vol 2, No 5
Chicago, IL—Whole genome sequencing was the topic of a session at the 2011 ASCO annual meeting in which specialists discussed the implications of “genome-forward medicine” in lung cancer.
Read Article
Page 3 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma